Ashley Mansell

Company: Bacainn Therapeutics/Hudson Institute of Medical Research
Job title: Senior Director of Research & Development/Principal Investigator
Seminars:
BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation 11:30 am
BT032 is a novel first in class NLRP1 and NLRP3 inhibitor BT032 directly targets NLRP1 and NLRP3 activity BT032 reduces IAV-induced pulmonary inflammation in vivoRead more
day: Day 1 - Track B - Morning